Screener
HealthEquity HQY Sales & Marketing
Sales & Marketing at other companies
Other financials
Where this comes from
Reported directly by HealthEquity in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: HealthEquity’s 10-Q, filed May 28, 2026.
- Filed
- May 28, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0001428336-26-000028
| (in thousands, except per share data) | Three months ended April 30, 2026 | Three months ended April 30, 2025 |
|---|---|---|
| Total cost of revenue | 98,329 | 106,533 |
| Gross profit | 256,312 | 224,311 |
| Operating expenses | ||
| Sales and marketing | 26,833 | 25,984 |
| Technology and development | 67,767 | 61,436 |
| General and administrative | 31,131 | 25,536 |
| Amortization of acquired intangible assets | 26,515 | 27,002 |
| Merger integration | 1,113 | 1,275 |
Item 1. Financial statements
FAQ
- What is HealthEquity's sales & marketing?
- HealthEquity (HQY) reported sales & marketing of $26.83M in Q1 2026.
- How has HealthEquity's sales & marketing changed year-over-year?
- HealthEquity's sales & marketing increased by 3.3% year-over-year, from $25.98M to $26.83M.
- What is the long-term trend for HealthEquity's sales & marketing?
- Over 4 years (2022 to 2026), HealthEquity's sales & marketing has grown at a 12.9% compound annual growth rate (CAGR), from $58.61M to $95.24M.
- What does sales & marketing mean?
- Costs of selling products and services including sales force compensation, commissions, marketing campaigns, trade shows, and customer acquisition expenses.
Ask your AI about HealthEquity's sales & marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude